HONG KONG -- A third dose of Sinovac's COVID vaccine does not provide sufficient protection against the omicron variant, new research reveals, contradicting the Chinese vaccine maker's pronouncement that it does.
The University of Hong Kong (HKU) and Chinese University of Hong Kong conducted the study, finding that a third shot of what is one of the world's most widely used COVID vaccines does not produce enough levels of virus-neutralizing antibodies. A third dose of a vaccine produced by Pfizer and BioNTech, however, significantly improved protection for those who had previously taken two doses of Sinovac, also known as CoronaVac, the research shows.
